JP2016520081A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520081A5 JP2016520081A5 JP2016513986A JP2016513986A JP2016520081A5 JP 2016520081 A5 JP2016520081 A5 JP 2016520081A5 JP 2016513986 A JP2016513986 A JP 2016513986A JP 2016513986 A JP2016513986 A JP 2016513986A JP 2016520081 A5 JP2016520081 A5 JP 2016520081A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- composition
- regulatory
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 16
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 8
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 210000003289 regulatory T cell Anatomy 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 210000000056 organ Anatomy 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- 230000000961 alloantigen Effects 0.000 claims 3
- 238000004113 cell culture Methods 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000003018 immunosuppressive agent Substances 0.000 claims 3
- 229940124589 immunosuppressive drug Drugs 0.000 claims 3
- 229930105110 Cyclosporin A Natural products 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 claims 2
- 229960002170 azathioprine Drugs 0.000 claims 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- SWZTYAVBMYWFGS-UHFFFAOYSA-N fingolimod hydrochloride Chemical compound Cl.CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 SWZTYAVBMYWFGS-UHFFFAOYSA-N 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 108010074605 gamma-Globulins Proteins 0.000 claims 2
- 229960000681 leflunomide Drugs 0.000 claims 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229950000844 mizoribine Drugs 0.000 claims 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 2
- 229960004866 mycophenolate mofetil Drugs 0.000 claims 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 2
- 229960002930 sirolimus Drugs 0.000 claims 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 229940122739 Calcineurin inhibitor Drugs 0.000 claims 1
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 claims 1
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 108010058846 Ovalbumin Proteins 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical group C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- 229940009456 adriamycin Drugs 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 229960002092 busulfan Drugs 0.000 claims 1
- 229940046731 calcineurin inhibitors Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960000556 fingolimod Drugs 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229940092253 ovalbumin Drugs 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361824590P | 2013-05-17 | 2013-05-17 | |
| US61/824,590 | 2013-05-17 | ||
| PCT/US2014/037195 WO2014186193A1 (en) | 2013-05-17 | 2014-05-07 | T regulatory cells and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018171329A Division JP2018193404A (ja) | 2013-05-17 | 2018-09-13 | 調節性ｔ細胞及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016520081A JP2016520081A (ja) | 2016-07-11 |
| JP2016520081A5 true JP2016520081A5 (https=) | 2017-06-15 |
| JP6584387B2 JP6584387B2 (ja) | 2019-10-02 |
Family
ID=51898789
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016513986A Active JP6584387B2 (ja) | 2013-05-17 | 2014-05-07 | 調節性ｔ細胞及びその使用 |
| JP2018171329A Withdrawn JP2018193404A (ja) | 2013-05-17 | 2018-09-13 | 調節性ｔ細胞及びその使用 |
| JP2020108015A Pending JP2020158536A (ja) | 2013-05-17 | 2020-06-23 | 調節性ｔ細胞及びその使用 |
| JP2022194378A Pending JP2023016923A (ja) | 2013-05-17 | 2022-12-05 | 調節性ｔ細胞及びその使用 |
| JP2025065395A Withdrawn JP2025106512A (ja) | 2013-05-17 | 2025-04-11 | 調節性ｔ細胞及びその使用 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018171329A Withdrawn JP2018193404A (ja) | 2013-05-17 | 2018-09-13 | 調節性ｔ細胞及びその使用 |
| JP2020108015A Pending JP2020158536A (ja) | 2013-05-17 | 2020-06-23 | 調節性ｔ細胞及びその使用 |
| JP2022194378A Pending JP2023016923A (ja) | 2013-05-17 | 2022-12-05 | 調節性ｔ細胞及びその使用 |
| JP2025065395A Withdrawn JP2025106512A (ja) | 2013-05-17 | 2025-04-11 | 調節性ｔ細胞及びその使用 |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US20160046715A1 (https=) |
| JP (5) | JP6584387B2 (https=) |
| WO (1) | WO2014186193A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105026573A (zh) | 2012-11-28 | 2015-11-04 | 艾布维兹生物公司 | 用于单引物扩增的基因特异模板的制备 |
| CN111212654A (zh) * | 2017-06-20 | 2020-05-29 | 维埃拉生物科学公司 | 用激活的调节性t细胞治疗肝衰竭 |
| WO2019245039A1 (ja) | 2018-06-22 | 2019-12-26 | 株式会社Ｊｕｎｔｅｎ Ｂｉｏ | 感染性免疫寛容を惹起するための組成物 |
| AU2019288635A1 (en) | 2018-06-22 | 2021-01-21 | Junten Bio Co., Ltd. | Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte |
| KR20210024048A (ko) | 2018-06-22 | 2021-03-04 | 가부시키가이샤 준텐 바이오 | 복합 상태를 갖는 세포 혼합물을 이용한, 면역 관용을 유도하는 항체 및 유도된 림프구, 또한 유도된 림프구를 이용하는 세포 치료제 및 치료법 |
| KR102234394B1 (ko) * | 2019-03-08 | 2021-03-31 | 신지섭 | 타가면역세포배양방법, 그 방법으로 얻어진 면역세포배양액 및 이를 포함하는 면역세포치료제 |
| KR102216710B1 (ko) * | 2019-03-27 | 2021-02-17 | 신지섭 | Nk세포배양배지용 첨가조성물, 상기 첨가조성물을 이용한 nk세포배양방법 및 상기 배양방법으로 얻어진 피부트러블개선용 화장료조성물 |
| WO2022060874A1 (en) * | 2020-09-15 | 2022-03-24 | City Of Hope | Ex vivo expansion of regulatory t cells for suppression of graft versus host disease |
| US20250224392A1 (en) | 2022-03-31 | 2025-07-10 | Juntendo Educational Foundation | Method for evaluating quality of inducement inhibitory-t-cell formulation |
| EP4660297A1 (en) * | 2023-01-30 | 2025-12-10 | Juntendo Educational Foundation | Method for selectively inducing antigen-specific inductive regulatory t cells |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60141510D1 (de) * | 2000-04-11 | 2010-04-22 | Univ Southern California | Methode zur verhinderung der transplantatabstossung unter verwendung von tgf-beta zur induktion von t-suppressorzellen |
| JP5816627B2 (ja) * | 2009-10-27 | 2015-11-18 | イミュニカム・エイビイ | 抗原特異的ｔ細胞の増殖のための方法 |
| RU2013140471A (ru) * | 2011-02-02 | 2015-03-10 | Дженентек, Инк. | Дозирование для лечения антителами против egfl7 |
| AU2012250924B2 (en) * | 2011-05-02 | 2017-05-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| US20140186363A1 (en) * | 2011-06-03 | 2014-07-03 | University Of Zurich | Magea3 binding antibodies |
-
2014
- 2014-05-07 WO PCT/US2014/037195 patent/WO2014186193A1/en not_active Ceased
- 2014-05-07 US US14/783,258 patent/US20160046715A1/en not_active Abandoned
- 2014-05-07 JP JP2016513986A patent/JP6584387B2/ja active Active
-
2018
- 2018-09-13 JP JP2018171329A patent/JP2018193404A/ja not_active Withdrawn
-
2019
- 2019-11-11 US US16/680,405 patent/US20200079853A1/en not_active Abandoned
-
2020
- 2020-06-23 JP JP2020108015A patent/JP2020158536A/ja active Pending
-
2022
- 2022-12-05 JP JP2022194378A patent/JP2023016923A/ja active Pending
-
2025
- 2025-04-11 JP JP2025065395A patent/JP2025106512A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520081A5 (https=) | ||
| Szumilas et al. | Current status regarding immunosuppressive treatment in patients after renal transplantation | |
| Sarkozy et al. | Management of relapsed/refractory DLBCL | |
| Fraser et al. | A rapamycin-based GMP-compatible process for the isolation and expansion of regulatory T cells for clinical trials | |
| Fetter et al. | Skin-associated B cells in the pathogenesis of cutaneous autoimmune diseases—implications for therapeutic approaches | |
| Lindquist et al. | B cells and antibodies in Kawasaki disease | |
| Kooij et al. | P-glycoprotein acts as an immunomodulator during neuroinflammation | |
| Martino et al. | CART-cell therapy: recent advances and new evidence in multiple myeloma | |
| JP2025106512A (ja) | 調節性ｔ細胞及びその使用 | |
| Cvetkovski et al. | Strategies for liver transplantation tolerance | |
| Markouli et al. | Recent advances in adult post-transplant lymphoproliferative disorder | |
| JP2021516224A5 (https=) | ||
| MX2019000022A (es) | Células veto generadas a partir de linfocitos t de memoria. | |
| JP2013537187A5 (https=) | ||
| Chakupurakal et al. | Immunological effects in patients with steroid‐refractory graft‐versus‐host disease following treatment with basiliximab, a CD 25 monoclonal antibody | |
| Nenasheva et al. | The introduction of mesenchymal stromal cells induces different immunological responses in the lungs of healthy and M. tuberculosis infected mice | |
| JPWO2010067671A1 (ja) | 移植片対腫瘍効果を保存した免疫学的再構築促進剤または感染症予防剤 | |
| Sobkowiak-Sobierajska et al. | Management of chronic graft-vs.-host disease in children and adolescents with ALL: present status and model for a personalised management plan | |
| Ban et al. | Clinical Trial of Allogeneic Mesenchymal Stem Cell Therapy for Chronic Active Antibody‐Mediated Rejection in Kidney Transplant Recipients Unresponsive to Rituximab and Intravenous Immunoglobulin | |
| Bottomley et al. | Towards regulatory cellular therapies in solid organ transplantation | |
| Lu et al. | Dysplastic epithelial repair promotes the tissue residence of lymphocytes to inhibit alveolar regeneration post viral infection | |
| JP2019508056A5 (https=) | ||
| Otley | Skin disease in organ transplantation | |
| Cwykiel et al. | Cellular therapy models: ex vivo chimera model by cell fusion | |
| Kim et al. | Single step isolation and activation of primary CD3+ T lymphocytes using alcohol-dispersed electrospun magnetic nanofibers |